Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level Viremia

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5998-6000

  Li, Jonathan Z ^a   Gallien, Sebastien ^a,b   Do, Tri D ^c   Martin, Jeffrey N ^d   Deeks, Steven ^d   Kuritzkes, Daniel R ^a   Hatano, Hiroyu ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c Roche Molecular Diagnostics   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADHESION; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RISK; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION RATE; VIRAL LOAD; VIREMIA;

EID: 84868035487     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01217-12     Document Type: Article

References (13)

1. Cohen C. 2009. Low-level viremia in HIV-1 infection: consequences and implications for switchingtoanew regimen. HIV Clin. Trials 10:116-124.
2. Delaugerre C, et al. 2012. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One 7:e36673. doi:10.1371/journal.pone.0036673.
3. Gallien S, et al. 2011. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 25:665-669.
4. Geretti AM, et al. 2008. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir. Ther. 13:927-936.
5. Greub G, et al. 2002. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 16:1967-1969.
6. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. 2010. Antiret-roviral drug resistance in HIV-1-infected patients with low-level viremia. J. Infect. Dis. 201:1303-1307.
7. McConnell MJ, et al. 2011. Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia. J. Acquir. Immune Defic. Syndr. 58:446-449.
8. Nettles RE, et al. 2005. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293:817-829.
9. Nettles RE, et al. 2004. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39:1030-1037.
10. Taiwo B, et al. 2011. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J. Infect. Dis. 204:515-520.
11. Tang MW, Liu TF, Shafer RW. 2012. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology 55:98-101.
12. Tobin NH, et al. 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79:9625-9634.
13. von Wyl V, et al. 2012. Incidence of HIV-1 drug resistance among anti-retroviral treatment-naive individuals starting modern therapy combinations. Clin. Infect. Dis. 54:131-140.